Seeking Alpha

Jazz Pharmaceuticals (JAZZ) clocks a 14.7% gain after reporting Q2 revenue and adjusted EPS of...

Jazz Pharmaceuticals (JAZZ) clocks a 14.7% gain after reporting Q2 revenue and adjusted EPS of $64.6M (+60%) and $0.82, beating a consensus of $61.9M and $0.77. Sales of its flagship Xyrem drug for treating cataplexy rose 67% Y/Y. The company now expects 2011 adjusted EPS of $3.15-$3.25, ahead of a $3.07 consensus. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs